Product Reports Resources Pricing Login Book a demo

WuXi Biologics

Biotech & Life Sciences · Xuancheng, China · Founded 2000 · IPO 2017

WuXi Biologics - Discovery, Development, Manufacturing - CDMO - CMO. Spun out of WuXi AppTec

Valuation $17B
Revenue $3.47B
EBITDA $1.31B
Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue
Knowledge graph
News MiRABO Biotechnology raises $2.9M pre-Series A for its antibody drug AI Aug 20, 2026

Talent graph

WuXi Biologics's talent

Book a demo to see the people
Employees mapped 3,038 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 26 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

1 investor on WuXi Biologics's cap table

Sourced from Dealroom's funding and investor records.

Series B+ 1 investor entered at this stage
Dinghang Capital

Global footprint

Where WuXi Biologics has talent and traffic

Workforce by country
24 countries with
team presence
🇨🇳 China42.5%
🇮🇪 Ireland24.5%
🇺🇸 United States17.1%
🇩🇪 Germany8%
🇬🇧 United Kingdom4.1%
Top 5 of 24 shown
Web traffic by country
190K monthly visits
across markets
🇨🇳 China85.5%
🇺🇸 United States9.9%
🏳️ Korea1.7%
🏳️ Republic of1.5%
🇬🇧 United Kingdom1.1%
Top 5 markets shown

Patent intelligence

$95M patent portfolio · 423 active families

Estimated portfolio value
$95M
0.55% of market cap · 1.6× larger than top peer Viridian Therapeutics ($59M)
423 active patent families
Where WuXi Biologics innovates Antiendomysial antibodiesBiochemistryBioinformaticsCell biologyExpression vector

Where WuXi Biologics concentrates vs peers

Each axis is a top-10 topic across WuXi Biologics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

WuXi Biologics's 10 investments and acquisitions.

Every disclosed deal where WuXi Biologics appeared as a backer or acquirer, 2020–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

10 deals across WuXi Biologics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        WuXi Biologics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        10 of 10 deals

        Market sentiment

        What the market is saying about WuXi Biologics

        An AI-synthesized read of the highest-engagement posts about WuXi Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See WuXi Biologics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles